Patent Term Extension

ICR 201912-0651-003

OMB: 0651-0020

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement A
2020-01-30
Supplementary Document
2020-01-21
ICR Details
0651-0020 201912-0651-003
Active 201908-0651-012
DOC/PTO
Patent Term Extension
Revision of a currently approved collection   No
Regular
Approved without change 03/31/2020
Retrieve Notice of Action (NOA) 01/31/2020
  Inventory as of this Action Requested Previously Approved
03/31/2023 36 Months From Approved 03/31/2020
620 0 1,340
4,102 0 6,187
209,889 0 369,455

The patent term restoration portion of the Drug Price Competition and Patent Term Restoration Act of 1984 (P.L. 98-417), which is codified at 35 U.S.C. 156, permits the USPTO to extend the term of protection under a patent to compensate for delay during regulatory review and approval by the Food and Drug Administration (FDA) or United States Department of Agriculture (USDA). Only patents for drug products, medical devices, food additives, or color additives are potentially eligible for extension. The maximum length that a patent may be extended under 35 U.S.C. 156 is 5 years. The USPTO administers 35 U.S.C. 156 through 37 CFR 1.710-1.791. Separate from the extension provisions of 35 U.S.C. 156, the USPTO may in some cases extend the term of an original patent due to certain delays in the prosecution of the patent application, including delays caused by interference proceedings, secrecy orders, or appellate review by the Patent Trial and Appeal Board or a Federal court in which the patent is issued pursuant to a decision reversing an adverse determination of patentability. The patent term provisions of 35 U.S.C. 154(b), as amended by Title IV, Subtitle D of the Intellectual Property and Communications Omnibus Reform Act of 1999, require the USPTO to notify the applicant of the patent term adjustment in the notice of allowance and give the applicant an opportunity to request reconsideration of the USPTO’s patent term adjustment determination. The USPTO administers 35 U.S.C. 154 through 37 CFR 1.701-1.705. The public uses this information collection to file requests related to patent term extensions and reconsideration or reinstatement of patent term adjustments. The information in this collection is used by the USPTO to consider whether an applicant is eligible for a patent term extension or reconsideration of a patent term adjustment and, if so, to determine the length of the patent term extension or adjustment.

US Code: 35 USC 154-156 Name of Law: Drug Price Competition and Patent Term Restoration Act of 1984
  
None

Not associated with rulemaking

  84 FR 63857 11/19/2019
85 FR 5636 01/31/2020
No

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 620 1,340 0 0 -720 0
Annual Time Burden (Hours) 4,102 6,187 0 0 -2,085 0
Annual Cost Burden (Dollars) 209,889 369,455 0 0 -159,566 0
No
No
The USPTO estimates that this information collection will receive 720 fewer annual responses over the 3-year period covered by this renewal request. This adjustment also causes the number of burden hours for this activity to decrease 2,085 hours. Despite minor increases due to the rise in postage rates, the overall decrease in non-hourly costs is due to the decreased number of responses.

$16,769
No
    Yes
    No
No
No
No
Uncollected
Raul Tamayo 571 272-7728 raul.tamayo@uspto.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
01/31/2020


© 2024 OMB.report | Privacy Policy